BG105804A - 16-hydroxyestratrienes as selective acting estrogens - Google Patents
16-hydroxyestratrienes as selective acting estrogensInfo
- Publication number
- BG105804A BG105804A BG105804A BG10580401A BG105804A BG 105804 A BG105804 A BG 105804A BG 105804 A BG105804 A BG 105804A BG 10580401 A BG10580401 A BG 10580401A BG 105804 A BG105804 A BG 105804A
- Authority
- BG
- Bulgaria
- Prior art keywords
- estrogens
- 5ht2a
- hydroxyestratrienes
- uterus
- effect
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0055—Estrane derivatives not substituted in position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19906159A DE19906159A1 (de) | 1999-02-09 | 1999-02-09 | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
PCT/EP2000/001073 WO2000047603A2 (de) | 1999-02-09 | 2000-02-09 | 16-hydroxyestratriene als selektiv wirksame estrogene |
Publications (1)
Publication Number | Publication Date |
---|---|
BG105804A true BG105804A (en) | 2002-03-29 |
Family
ID=7897485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG105804A BG105804A (en) | 1999-02-09 | 2001-08-09 | 16-hydroxyestratrienes as selective acting estrogens |
Country Status (30)
Country | Link |
---|---|
EP (2) | EP1144431B1 (es) |
JP (1) | JP2002536455A (es) |
KR (1) | KR20010101822A (es) |
CN (1) | CN1346364A (es) |
AR (1) | AR034392A1 (es) |
AT (1) | ATE313553T1 (es) |
AU (1) | AU2909500A (es) |
BG (1) | BG105804A (es) |
BR (1) | BR0008076A (es) |
CA (1) | CA2359660A1 (es) |
CO (1) | CO5150223A1 (es) |
CZ (1) | CZ20012843A3 (es) |
DE (2) | DE19906159A1 (es) |
DK (1) | DK1144431T3 (es) |
EA (1) | EA200100828A1 (es) |
EE (1) | EE200100412A (es) |
ES (1) | ES2255983T3 (es) |
HK (1) | HK1046145A1 (es) |
HU (1) | HUP0200055A3 (es) |
IL (1) | IL144455A0 (es) |
MX (1) | MXPA01008065A (es) |
NO (1) | NO20013860L (es) |
NZ (1) | NZ513409A (es) |
PE (1) | PE20001461A1 (es) |
PL (1) | PL350360A1 (es) |
PT (1) | PT1144431E (es) |
SK (1) | SK11302001A3 (es) |
WO (1) | WO2000047603A2 (es) |
YU (1) | YU57201A (es) |
ZA (1) | ZA200107388B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10039199A1 (de) * | 2000-08-10 | 2002-02-21 | Schering Ag | Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen |
DE10048634A1 (de) * | 2000-09-27 | 2002-04-18 | Jenapharm Gmbh | 19-Nor-17alpha-pregna-1,3,5(10)-trien-17beta-ole mit einem 21, 16alpha-Laktonring |
DE10151365A1 (de) | 2001-10-17 | 2003-04-30 | Schering Ag | 17-Chlor-D-Homosteroide als selektive Estrogenrezeptorantagonisten |
DE10151114A1 (de) * | 2001-10-15 | 2003-04-17 | Schering Ag | 8ß-Substituierte-11ß-aryl-estra-2,3,5(10)-trienderivate |
DE10151363A1 (de) * | 2001-10-17 | 2003-05-08 | Schering Ag | Somatotrope Therapie |
US7414043B2 (en) | 2002-06-11 | 2008-08-19 | Schering Ag | 9-α-substituted estratrienes as selectively active estrogens |
DE10226326A1 (de) * | 2002-06-11 | 2004-01-15 | Schering Ag | 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene |
TWI392682B (zh) * | 2006-04-13 | 2013-04-11 | Sigma Tau Ind Farmaceuti | 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物 |
TWI389917B (zh) * | 2006-04-13 | 2013-03-21 | Sigma Tau Ind Farmaceuti | 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物 |
SE536263C2 (sv) * | 2011-12-21 | 2013-07-23 | Airqone Building Scandinavia Ab | Reningsanordning för gasmedium innefattande medel för kontrollerad tillförsel av joniserad luft |
EP3500265B1 (en) * | 2016-08-22 | 2023-10-04 | Or-Genix Therapeutics, Inc. | Estrogen receptor beta selective ligands |
WO2019041078A1 (en) * | 2017-08-28 | 2019-03-07 | Zhejiang Jiachi Pharmaceutical Development Ltd. | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES |
CN113056473A (zh) * | 2018-09-07 | 2021-06-29 | 达特茅斯学院托管理事会 | C19支架和甾体及其使用和制造方法 |
CN115154474A (zh) * | 2021-04-01 | 2022-10-11 | 中国人民解放军总医院 | 一种环菠萝蜜烷型三萜皂苷化合物在制备t细胞免疫抑制剂中的应用 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3079408A (en) * | 1963-02-26 | Ig-bisoxygenated iy-haloestra- | ||
US3103524A (en) * | 1963-09-10 | Ratetraene- | ||
GB823955A (en) * | 1955-09-01 | 1959-11-18 | Nepera Chemical Co Inc | Improvements in steroid compounds and method for manufacture of same |
GB804789A (en) * | 1956-02-06 | 1958-11-26 | Searle & Co | 16-alkylestratriene-3,16,17-triols and derivatives thereof |
US2779773A (en) * | 1956-05-23 | 1957-01-29 | Nepera Chemical Co Inc | Steroid 3, 16alpha-diols and process |
US3166473A (en) * | 1962-04-12 | 1965-01-19 | Mochida Pharm Co Ltd | New esters of 1, 3, 5-estratriene-3, 16, 17-triol and novel pharmaceutical compositions containing new esters of 1, 3, 5-estratriene-3, 16, 17-triol and esters of 1, 3, 5-estratriene-3, 16, 17-triol |
NL124324C (es) * | 1964-01-24 | |||
FR4339M (es) * | 1965-03-29 | 1966-08-08 | ||
FR5099M (es) * | 1966-01-12 | 1967-05-22 | ||
US3449383A (en) * | 1967-02-16 | 1969-06-10 | Searle & Co | 17-oxygenated estra-1,3,5(10)-triene-3,11beta,16-triols,ethers and esters thereof |
US3470159A (en) * | 1967-07-13 | 1969-09-30 | American Home Prod | Estra-1,3,5(10),7-tetraenes and process of preparation |
CH537916A (de) * | 1969-02-27 | 1973-06-15 | Ciba Geigy Ag | Verfahren zur Herstellung eines neuen Östratriols |
CH538460A (de) * | 1969-02-27 | 1973-06-30 | Ciba Geigy Ag | Verfahren zur Herstellung eines neuen hochwirksamen Östratriols |
GB1235642A (en) * | 1969-02-27 | 1971-06-16 | Ciba Geigy | A new oestratriol and a process for its manufacture |
FR2034569B1 (es) * | 1969-02-27 | 1973-07-13 | Ciba Geigy Ag | |
US3600705A (en) * | 1969-02-27 | 1971-08-17 | Gen Electric | Highly efficient subcritically doped electron-transfer effect devices |
US3622670A (en) * | 1969-08-22 | 1971-11-23 | American Home Prod | Method of inducing ovulation |
IL38806A0 (en) * | 1971-03-05 | 1972-04-27 | Ciba Geigy Ag | Pharmaceutical compositions comprising estrogens and anthracene derivatives |
US3766224A (en) * | 1971-06-03 | 1973-10-16 | Sandoz Ag | 15-methyl-substituted steroids |
US3946052A (en) * | 1975-06-16 | 1976-03-23 | Stanford Research Institute | 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity |
JPS5265259A (en) * | 1975-11-27 | 1977-05-30 | Takeda Chem Ind Ltd | Synthesis of 16beta-alkylestradiol or its 17-esters |
NL7613248A (nl) * | 1976-11-26 | 1978-05-30 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroid- esters. |
DD145919B1 (de) * | 1978-06-28 | 1982-06-30 | Kurt Ponsold | Verfahren zur herstellung von 14,1 -methylenderivaten der oestranreihe |
SE8305596D0 (sv) * | 1983-10-12 | 1983-10-12 | Leo Ab | A selective acylation method |
DE3510555A1 (de) * | 1985-03-21 | 1986-09-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | Estriolester |
US4705783A (en) * | 1985-06-25 | 1987-11-10 | Sri International | 9α, 11β-substituted and 11β-substituted estranes |
HU208150B (en) * | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
SU1761760A1 (ru) * | 1990-07-02 | 1992-09-15 | Всесоюзный Эндокринологический Научный Центр Амн Ссср | Способ получени 11-нитратов 9 @ , 11 @ -диоксистероидов |
DE4239946C2 (de) * | 1992-11-27 | 2001-09-13 | Jenapharm Gmbh | Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung |
DE4322186A1 (de) * | 1993-07-03 | 1995-01-12 | Jenapharm Gmbh | Oral estrogen wirksame Ester des 14alpha, 15alpha-Methylen-estradiols |
DE4326240A1 (de) * | 1993-08-02 | 1995-02-09 | Schering Ag | 15,15-Dialkyl-substituierte Derivate des Estradiols |
US5554603A (en) * | 1993-09-17 | 1996-09-10 | The United States Of America As Represented By The Department Of Health And Human Services | Orally active derivatives of 1,3,5(10)-estratriene |
DE4338314C1 (de) * | 1993-11-10 | 1995-03-30 | Jenapharm Gmbh | Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen |
SE9502921D0 (sv) * | 1995-08-23 | 1995-08-23 | Astra Ab | New compounds |
DE19635525A1 (de) * | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
DE19815060A1 (de) * | 1998-04-03 | 1999-10-14 | Jenapharm Gmbh | Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie |
-
1999
- 1999-02-09 DE DE19906159A patent/DE19906159A1/de not_active Withdrawn
-
2000
- 2000-02-08 PE PE2000000093A patent/PE20001461A1/es not_active Application Discontinuation
- 2000-02-08 CO CO00007990A patent/CO5150223A1/es unknown
- 2000-02-09 CN CN00803613A patent/CN1346364A/zh active Pending
- 2000-02-09 SK SK1130-2001A patent/SK11302001A3/sk unknown
- 2000-02-09 CZ CZ20012843A patent/CZ20012843A3/cs unknown
- 2000-02-09 ES ES00907539T patent/ES2255983T3/es not_active Expired - Lifetime
- 2000-02-09 YU YU57201A patent/YU57201A/sh unknown
- 2000-02-09 EP EP00907539A patent/EP1144431B1/de not_active Expired - Lifetime
- 2000-02-09 CA CA002359660A patent/CA2359660A1/en not_active Abandoned
- 2000-02-09 AT AT00907539T patent/ATE313553T1/de not_active IP Right Cessation
- 2000-02-09 HU HU0200055A patent/HUP0200055A3/hu unknown
- 2000-02-09 EE EEP200100412A patent/EE200100412A/xx unknown
- 2000-02-09 DE DE50011908T patent/DE50011908D1/de not_active Expired - Fee Related
- 2000-02-09 JP JP2000598520A patent/JP2002536455A/ja active Pending
- 2000-02-09 MX MXPA01008065A patent/MXPA01008065A/es unknown
- 2000-02-09 KR KR1020017009989A patent/KR20010101822A/ko not_active Application Discontinuation
- 2000-02-09 DK DK00907539T patent/DK1144431T3/da active
- 2000-02-09 WO PCT/EP2000/001073 patent/WO2000047603A2/de active IP Right Grant
- 2000-02-09 EA EA200100828A patent/EA200100828A1/ru unknown
- 2000-02-09 EP EP05075149A patent/EP1580192A2/de not_active Withdrawn
- 2000-02-09 AU AU29095/00A patent/AU2909500A/en not_active Abandoned
- 2000-02-09 AR ARP000100553A patent/AR034392A1/es not_active Application Discontinuation
- 2000-02-09 PL PL00350360A patent/PL350360A1/xx not_active Application Discontinuation
- 2000-02-09 PT PT00907539T patent/PT1144431E/pt unknown
- 2000-02-09 IL IL14445500A patent/IL144455A0/xx unknown
- 2000-02-09 NZ NZ513409A patent/NZ513409A/xx unknown
- 2000-02-09 BR BR0008076-4A patent/BR0008076A/pt not_active IP Right Cessation
-
2001
- 2001-08-08 NO NO20013860A patent/NO20013860L/no not_active Application Discontinuation
- 2001-08-09 BG BG105804A patent/BG105804A/xx unknown
- 2001-09-06 ZA ZA200107388A patent/ZA200107388B/en unknown
-
2002
- 2002-10-17 HK HK02107553.2A patent/HK1046145A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20024907D0 (no) | 8<beta>-substituerte-11<beta>-pentyl- og 11<beta>-heksyl- östra-1,3,5(10)-trienderivater | |
Lieberburg et al. | The effects of an inhibitor of aromatization (1, 4, 6-androstatriene-3, 17-dione) and an anti-estrogen (Cl-628) on in vivo formed testosterone metabolites recovered from neonatal rat brain tissues and purified cell nuclei. Implications for sexual differentiation of the rat brain | |
BG105804A (en) | 16-hydroxyestratrienes as selective acting estrogens | |
IL146281A0 (en) | Indoline derivatives as progesterone antagonists | |
EP2305694A3 (en) | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | |
CA2124932A1 (en) | Sex steroid activity inhibitors | |
HUP0102913A3 (en) | Use of biogenic estrogen sulfamates for producing pharmaceutical compositions for hormone replacement therapy | |
AU1855201A (en) | 18-nor-steroids as selectively active estrogens | |
RS107004A (en) | 9-alpha-substituted estratrienes as selectively active estrogen | |
TN2010000007A1 (en) | 8-beta- substituted estratrienes as selectively active estrogens | |
HK1044542B (zh) | 由11β-芳基-17,17-螺硫羥烷取代的類固醇 | |
EP1025098A4 (en) | BENTZOTHIOPHENE | |
PL352029A1 (en) | 14-beta-h-sterols, pharmaceutical compositions containing these sterols and use of these derivatives for obtaining drugs to regulate meioses | |
UY26967A1 (es) | Derivados 8beta-sustituidos de 11beta-pentil y 11beta-hexil-estra-1,3,5(10)-trieno.- |